Injectafer, made by Daiichi Sankyo, is a ferric carboxymaltose injection treatment for iron deficiency in adult patients with heart failure to improve exercise capacity, according to a June 5 company news release. It has already been approved in 86 countries since 2007 and is the most extensively studied IV iron treatment.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
